Skip to search formSkip to main contentSkip to account menu

Lirilumab

Known as: IPH2102 
A fully humanized monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Upon… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

BMS-986015
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML.
e18505Background: Lack of KIR-HLA class I interactions has been associated with NK-mediated antitumor efficacy in AML patients… 
2016
2016
Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid…
2015
2015
A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL…
3065 Background: Inhibitory Killer Immunoglobulin-like receptors (KIRs) negatively regulate the killing, by NK cells, of tumors… 
2014
2014
A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
TPS3115 Background: Killer cell immunoglobulin-like receptor (KIR) and programmed death-1 (PD-1) are immune receptors that… 
2014
2014
IMMUNOBIOLOGY Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD 20 antibodies
Immune checkpoint blockade represents a promising cancer therapy that aims to restore an efficient antitumoral response mediated… 
2013
2013
A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced…
TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell immunoglobulin-like… 
2013
2013
A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced…
TPS3106 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell immunoglobulin-like… 
2013
2013
Abstract 493: Antitumoral efficacy of therapeutic human anti-KIR antibody (BMS-986015/IPH2102) in a preclinical xenograft tumor model.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Natural Killer cells (NK cells) are lymphocytes able… 
2013
2013
Etudes pré-clinique et clinique de l'anticorps immunomodulateur Lirilumab visant à augmenter la réponse anti-tumorale des cellules NK
L’activite anti-tumorale des cellules NK est regulee par des recepteurs de surface activateurs et inhibiteurs qui reconnaissent… 
2011
2011
Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear…
Abstract 1865 Despite significant improvements in the treatment of multiple myeloma (MM), this progressive malignancy of antibody… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)